G1 Therapeutics

$26.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (+1.62%) Today
+$1.06 (+4.22%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GTHX and other stocks, options, and ETFs commission-free!

About GTHX

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC. The listed name for GTHX is G1 Therapeutics, Inc. Common Stock.

CEO
Jack Bailey
Employees
104
Headquarters
Research Triangle Park, North Carolina
Founded
2008
Market Cap
996.50M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.88M
High Today
$25.50
Low Today
$24.40
Open Price
$25.27
Volume
1.29M
52 Week High
$37.07
52 Week Low
$8.80

GTHX News

Benzinga5h

Recap: G1 Therapeutics Q4 Earnings

Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% y

GTHX Earnings

-$0.98
-$0.65
-$0.33
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.87 per share
Actual
-$0.67 per share
Replay Earnings Call

You May Also Like

BCX
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure